Is Insomnia a Modifiable Risk Factor for Major Depressive Disorder
This study will determine the effectiveness of cognitive behavioral therapy (CBT) in treating insomnia symptoms that are secondary to depression. This study will also determine how long the benefits of CBT will last and how the recurrence of insomnia is associated with the onset of new depressive episodes.
NCT00255905 — Depression
Status: Completed
http://inclinicaltrials.com/depression/NCT00255905/
Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale
The objective of the present study is to evaluate the effectiveness of postnatal depression screening by comparing the mental health outcome (at 6 months postpartum) of mothers under the Edinburgh Postnatal Depression Scale (EPDS) screening programme versus usual clinical practice (usual practice), using randomized controlled trial design. With the use of the EPDS for the screening of postnatal depression, it is expected that more mothers in need of intervention (including mental health intervention, guidance in childcare and parenting, counseling in family relationships, etc) will be picked up and offered appropriate intervention, compared to the usual practice. It is hypothesized that the mental health of the group of women under the EPDS screening programme will be better than those under the usual practice, on subsequent follow-up.
NCT00251342 — Depression, Postpartum
Status: Recruiting
http://inclinicaltrials.com/depression-postpartum/NCT00251342/
Depression-Diabetes Mechanisms: Urban African Americans
African-Americans suffer from increased prevalence of both type 2 diabetes and diabetes complications, reflecting a combination of psychobehavioral factors as well as metabolic dysfunction. In this process, depression may contribute to both the genesis of type 2 diabetes (through impact on neurohormonal activation, inflammatory mediators, and insulin resistance), and difficulties in management (through decreased adherence to diet plans, medication, and scheduled appointments). The preliminary data from the Grady Diabetes Clinic indicates that depression may be common in African-Americans with diabetes, that depression is a factor in non-adherence, and that non-adherence leads to poor glycemic control - a direct cause of diabetes complications. What is not known is: how treatment of depression could lead to both neurohormonal and psychobiological improvement, with improved patient adherence and glycemic control.
NCT00209170 — Depression
Status: Completed
http://inclinicaltrials.com/depression/NCT00209170/
Factors of Treatment Response in Major Depressive Disorder
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
NCT00200902 — Depression
Status: Completed
http://inclinicaltrials.com/depression/NCT00200902/
Bipolar Depression Assessment Study on Tx Response
The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).
NCT00191399 — Depression, Bipolar
Status: Completed
http://inclinicaltrials.com/depression-bipolar/NCT00191399/
Open-Label Study of Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar and Bipolar Spectrum Disorder
This is an 8-week open label study of bupropion SR in the treatment of youth with bipolar depression with adequate mood stabilization. All youth will be closely monitored for treatment emergent manic activation and drug-drug interactions with ongoing antimanic agents. The main objective of this study is to assess the safety and effectiveness of bupropion SR in the treatment of bipolar depression in children and adolescents.
NCT00181896 — Depression
Status: Terminated
http://inclinicaltrials.com/depression/NCT00181896/
The purpose of this study was to discuss the relation of mastery, social support and depression in patients with depressive disorder. Cross-sectional quantitive study and purposive sampling method were designed. Data collection and analysis was conducted through structural questionnaires (including demographics, social support scale, mastery scale, CESD scale) at a medical center in Taipei. Results showed that patients with depression whose degree of depression was negative correlated with mastery and social support, and mastery was positive correlated with social support. Regression statistics results showed that mastery, social support, age, loss of jobs can predict degree of depression up to 60 percent. The mastery was strongest independent predictable factor to degree of depression, and had partial or total mediate effects to age, loss of jobs, financial condition, and social support. The result of this study suggested that clinically the care of patients with depression should focus on their confidence in mastery and provide strategies to promote their confidence in mastery, which can effectively reduce the degree of depression of those patients.
NCT00172848 — Depression
Status: Completed
http://inclinicaltrials.com/depression/NCT00172848/
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
NCT00018174 — Depression
Status: Completed
http://inclinicaltrials.com/depression/NCT00018174/
Evaluation of Access to Screening for Post-partum Depression Via the Postnatal Interview Within 8 Weeks of Birth in Women Who Have Gave Birth at the Troyes Hospital ( DepressionPP )
Post-partum depression is defined as a depressive disorder with onset of symptoms in the year following childbirth. Several international studies have reported a prevalence of this condition of around pathology of around 15%. Santé publique France's 2021 national perinatal survey corroborated these figures, finding a prevalence of post-partum depression in France of in France of 16.7%. It is therefore a frequent pathology that can cause complications for both mother and child. The complications both for the mother and for the mother-child bond. Indeed, post-partum depression can lead to an increased risk of infanticide, weaker mother-child attachment, and altered parental behaviour. post-partum depression can lead to maternal suicide (the second leading cause cause of maternal mortality in France). Despite the potential seriousness of severe depression and its impact on the on the mother-child bond, just under half of those suffering from severe depression suffering from severe depression consult a healthcare professional. Fear of being judged or stigmatised, linked to misperceptions about the episode, is one of the main obstacles to consultation. Of being judged or stigmatised, linked to erroneous representations of the depressive episode. Given the scale of this condition, and the difficulties young mothers face in seeking help for young mothers to seek help, it is vital to screen postpartum women as widely and post-partum women as early as possible. In view of the extent of this condition and the difficulties young mothers have in seeking help for young mothers, it is vital to screen post-partum women as widely and as post-partum. With this in mind, from July 2022, a compulsory early post-natal interview has been introduced, designed to screen for postpartum depression.
NCT06469476 — Depression, Postpartum
Status: Recruiting
http://inclinicaltrials.com/depression-postpartum/NCT06469476/
The First Affiliated Hospital of Xi'an Jiaotong University
The patients with depression were observed and followed up to evaluate the changes of symptoms and cognitive function in patients with depression at different time points before and after drug treatment. At the same time, immunometabolism indicators in serum, urine and stool were detected to screen out immunoinflammatory markers related to cognitive function and treatment response in patients with depression, hoping to provide a new strategy for optimal treatment of depression.
NCT06100302 — Depression
Status: Recruiting
http://inclinicaltrials.com/depression/NCT06100302/